Regal Partners Ltd Has $122.64 Million Stake in Sanofi $SNY

Regal Partners Ltd increased its stake in shares of Sanofi (NASDAQ:SNY) by 33.2% during the first quarter, HoldingsChannel reports. The institutional investor owned 2,545,432 shares of the company’s stock after buying an additional 633,782 shares during the quarter. Sanofi accounts for about 6.7% of Regal Partners Ltd’s investment portfolio, making the stock its 7th largest holding. Regal Partners Ltd’s holdings in Sanofi were worth $122,639,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently bought and sold shares of the company. Aberdeen Group plc increased its stake in shares of Sanofi by 22.7% in the 4th quarter. Aberdeen Group plc now owns 467,241 shares of the company’s stock valued at $22,642,000 after acquiring an additional 86,314 shares in the last quarter. Benson Investment Management Company Inc. bought a new position in Sanofi during the fourth quarter worth $5,424,000. Euro Pacific Asset Management LLC acquired a new stake in Sanofi in the fourth quarter worth $2,111,000. Assetmark Inc. grew its holdings in Sanofi by 24.2% in the fourth quarter. Assetmark Inc. now owns 443,668 shares of the company’s stock worth $21,500,000 after purchasing an additional 86,496 shares during the period. Finally, HF Advisory Group LLC increased its stake in Sanofi by 131.5% in the fourth quarter. HF Advisory Group LLC now owns 71,708 shares of the company’s stock valued at $3,475,000 after purchasing an additional 40,738 shares in the last quarter. 14.03% of the stock is owned by institutional investors.

Sanofi Stock Performance

Shares of Sanofi stock opened at $45.54 on Wednesday. Sanofi has a 52 week low of $40.89 and a 52 week high of $52.68. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. The business has a 50 day moving average price of $43.49 and a 200-day moving average price of $45.29. The company has a market cap of $110.41 billion, a PE ratio of 12.72, a price-to-earnings-growth ratio of 1.12 and a beta of 0.34.

Wall Street Analysts Forecast Growth

SNY has been the topic of a number of research analyst reports. Argus raised shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Morgan Stanley set a $49.00 price target on Sanofi in a research note on Wednesday, July 8th. Citigroup restated a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price on the stock. in a report on Monday, April 20th. Finally, Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $49.50.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.